Home > Gynaecological Oncology > Ovarian Cancer
    • FILTER YOUR SEARCH
    Content Type:

    • Ovarian Cancer

    An Introduction to Ovarian Cancer

    Before 2016 the prognosis for patients with ovarian cancer was poor, and treatment options were limited. However, the introduction of bevacizumab followed by PARP inhibitors transformed outcomes in patients with BRCA1/2 mutation. Anti-angiogenic agents, immuno-oncology agents, combinations of these agents and hyperthermic intraperitoneal chemotherapy are currently being investigated and show promise for the future.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.

    Ovarian Cancer Content

    Breast Cancer, Genitourinary Cancers, Ovarian Cancer
    touchCONGRESS
    Antibody-drug conjugates for patients with solid tumours: Practical analysis of the latest data from ESMO 2020
    CME ACCREDITED Mikel Ross, MSN, RN Watch Time: 68 mins

    Watch this two-part activity discussing the latest developments in antibody-drug conjugates for solid tumours. Filmed following presentations at ESMO 2020. Part 1: Watch internationally renowned expert Mikel Ross review key data from the congress Watch Now Part 2: Choose from leading experts who discuss what the latest data mean for global and regional practice Select An Interview

    Learning objectives
    Learning Objectives
    • Recognize the antibody drug conjugates (ADCs) that are available for the treatment of solid tumours
    • Summarize how emerging and evolving ADCs may improve outcomes for patients with solid tumours
    • Discuss practical strategies for the management of adverse events associated with approved ADCs for solid tumours
    Ovarian Cancer
    touchCONGRESS
    Keeping pace with the PARP inhibitors: What are the latest data on their role in maintenance treatment for ovarian cancer?
    CME ACCREDITED Dr Bradley Monk, Dr Domenica Lorusso, Prof. Isabelle Ray-Coquard Watch Time: 48 mins

    Stay up to date with the latest developments in PARP inhibition for the first-line maintenance treatment of advanced ovarian cancer with our expert update from the virtual SGO and ASCO annual meetings 2020. Part 1: Watch internationally renowned expert Dr Bradley Monk review key data from the virtual SGO and ASCO annual meetings 2020 Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice

    Learning objectives
    Learning Objectives
    • Discuss the use of PARP inhibitor monotherapy in first-line maintenance treatment
    • Describe the role of PARP inhibitors in combination first-line maintenance treatment
    • Recall the latest safety data for PARP inhibitor maintenance treatment
    Ovarian Cancer
    touchPANEL DISCUSSION
    PARP inhibitor maintenance treatment in advanced ovarian cancer: The who, what and how?
    CME ACCREDITED Dr Susana Banerjee, Dr Antonio González-Martín, Dr Kathleen Moore Watch Time: 35 mins

    Watch a panel of internationally renowned ovarian cancer experts discuss the use of PARP inhibitors for maintenance treatment in advanced ovarian cancer.  

    Learning objectives
    Learning Objectives
    • Describe the latest data for PARP inhibitors in the first-line maintenance treatment setting
    • Discuss approaches to select the most appropriate PARP inhibitor for each patient
    • Interpret safety data for PARP inhibitors to help mitigate and manage adverse events
    Ovarian Cancer
    Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors
    Robert L Coleman, Jonathan A Ledermann

    European Oncology & Haematology. 2019;15(1):29–40 DOI: https://doi.org/10.17925/EOH.2019.15.1.29

    Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]

    Gynaecological Oncology, Ovarian Cancer
    Advances in the Treatment of Endometrial and Ovarian Cancer
    David G Mutch

    Oncology & Hematology Review. 2019;15(1):23–4 DOI: https://doi.org/10.17925/OHR.2019.15.1.23

    Gynecological malignancies can be difficult to treat. Ovarian cancer carries with it the worst prognosis of all gynecological cancers. Approximately 75% of patients with epithelial ovarian cancer are diagnosed with advanced disease which is curable only in a minority of cases, resulting in a 5-year overall survival rate of only 20–30%. However, survival at all […]

    Ovarian Cancer
    touchINSIGHT
    Olaparib as a Maintenance Therapy for Ovarian Cancer and its use in BRCA-related Metastatic Breast Cancer
    Watch Time: 10 mins

    Recent results from trials with olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, are discussed in this Insight. Positive data and regulatory approvals are demonstrating that targeting the underlying genetic causes of a cancer can be a powerful tool for the development of new treatments with efficacy across different cancer types.

    Gynaecological Oncology, Immunotherapy, Ovarian Cancer
    Bevacizumab in the Management of Epithelial Ovarian Cancer
    Maurie Markman

    Oncology & Hematology Review (US), 2013;9(2):129–131 DOI: https://doi.org/10.17925/OHR.2013.09.2.129

    Epithelial ovarian cancer has long been recognized as being highly sensitive to cytotoxic chemotherapy, with anticipated objective response to platinum-based chemotherapy of approximately 70-85%1. Furthermore, overall survival (OS) for women presenting with advanced disease has been documented to have improved over the past few decades,2 although unfortunately the majority of responding patients ultimately experience recurrence […]

    Gynaecological Oncology, Ovarian Cancer
    Squamous Cell Carcinoma Arising in a Mature Cystic Teratoma of the Ovary: A Case Series and Review of the Literature
    James R Powell, Krishnayan Haldar

    European Oncology & Haematology, 2013;9(1):17–20 DOI: https://doi.org/10.17925/EOH.2013.09.1.17

    Mature cystic teratomas (also called dermoid cysts) account for about 30–45 % of all ovarian neoplasms and around 60 % of all benign tumours arising in the ovary.1 Malignant transformation of the various mature tissue components of a dermoid cyst is rare and the reported incidence is 0.17–1.4 %.2,3 Squamous cell carcinoma (SCC), arising from […]

    Gynaecological Oncology, Ovarian Cancer
    NGR-hTNF plus Doxorubicin in Relapsed Ovarian Carcinoma
    Domenica Lorusso, Maria Mancini, Italo Sarno

    European Oncology & Haematology, 2013;9(1):9–12 DOI: https://doi.org/10.17925/EOH.2013.09.1.9

    Ovarian cancer (OC) is the most lethal gynaecological cancer. In 2010, approximately 21,880 new cases and 13,850 deaths occurred in the US,1 while in the EU in 2004 the incidence of newly diagnosed cases was 42,700 with a mortality of 12/100,000 women/year.2 The current treatment of OC involves aggressive cytoreductive surgery followed by platinum- and […]

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72